AI Article Synopsis
- Dyslipidemia is a significant risk factor for worsening diabetic kidney disease, prompting this study to investigate its prevalence among diabetic patients with overt nephropathy.
- The study included 72 diabetic patients with overt nephropathy and 36 control patients, analyzing their fasting lipid profiles, blood sugars, and kidney function.
- Results showed that patients with nephropathy had notably higher total cholesterol and triglycerides, and treating dyslipidemia aggressively could help slow down kidney disease progression.
Article Abstract
Background: Dyslipidemia has been identified as a risk factor for the development and progression of diabetic renal disease.
Objective: This study was done to determine the prevalence of dyslipidemia among diabetic patients with overt nephropathy.
Materials And Methods: A total of 72 diabetic patients with overt diabetic nephropathy and 36 age- and sex-matched normoalbuminuric diabetic patients were studied. Their fasting lipid profile, fasting blood sugar, and renal function tests were evaluated.
Results: Total serum cholesterol and serum triglycerides were significantly higher in patients with overt diabetic nephropathy compared to the controls; 66.7% and 62.5% versus 36.1% and 30.6%, respectively ( P = 0.003 and 0.002, respectively).
Conclusions: Diabetic patients with overt diabetic nephropathy have significant dyslipidemia and aggressive lipid lowering in these patients may retard their progression to end-stage renal disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4103/1119-3077.84009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Digital Home-Based Self-Monitoring System for People with Heart Failure: Protocol for Development of SmartHeart and Evaluation of Feasibility and Acceptability.
JMIR Res Protoc
January 2025
School of Exercise and Nutrition Sciences, Institute for Physical Activity and Nutrition, Deakin University, Burwood, Australia.
Background: Heart failure (HF) is a chronic, progressive condition where the heart cannot pump enough blood to meet the body's needs. In addition to the daily challenges that HF poses, acute exacerbations can lead to costly hospitalizations and increased mortality. High health care costs and the burden of HF have led to the emerging application of new technologies to support people living with HF to stay well while living in the community.
View Article and Find Full Text PDFMixed Comparative Evaluation of a Training Program Dedicated to Cystic Fibrosis Reference Centers: Protocol for the Pilot Implementation of Shared Decision-Making in the Treatment of Diabetes in Adult Patients With Cystic Fibrosis.
JMIR Res Protoc
January 2025
Cystic Fibrosis Center, Department of Internal Medicine, Hospices Civils de Lyon, Research on Healthcare Performance U1290 Inserm, Lyon 1 University, Lyon, France.
Background: Diabetes affects half of the patients with cystic fibrosis who are aged 30 years and older. Diabetes progresses asymptomatically over a long period of time. Two treatment options are possible: start insulin as soon as cystic fibrosis diagnosis is made with the additional constraints of cystic fibrosis or wait while monitoring the patient's clinical condition and start insulin when diabetes symptoms develop and therefore later.
View Article and Find Full Text PDFThe Use of Acellular Dermal Matrix May Not Increase 30-Day Complications in Direct-to-Implant Breast Reconstruction: A Multi-institutional Analysis of 10,177 Cases.
Ann Plast Surg
January 2025
From the Division of Plastic Surgery, Department of Surgery, Yale School of Medicine, New Haven, CT.
Background: Direct-to-implant (DTI) breast reconstruction offers immediate aesthetic and psychological benefits, but the role of acellular dermal matrix (ADM) remains debated. Using a multi-institutional database, this study evaluates and compares outcomes between ADM-assisted and non-ADM DTI procedures.
Methods: The American College of Surgeons National Surgical Quality Improvement Program database from 2008 to 2022 was queried to identify female patients who underwent DTI breast reconstruction for oncological purposes.
Thyroid Nodules with Indeterminate Cytology and Negative Molecular Profile: Prevalence of Malignancy and Practice Paradigms for Surveillance.
Thyroid
January 2025
Division of Endocrinology, Diabetes and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
In the era of molecular testing, thyroid nodules with indeterminate cytology are increasingly being managed nonoperatively. The false-negative rates of these molecular tests, and therefore missed malignancies, are not well defined in real-world clinical practice. This retrospective study of patients undergoing fine needle aspiration (FNA) biopsy at our health system between November 2017 and March 2022 included nodules with The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) III and IV cytology and negative, currently negative, or negative but limited ThyroSeq version 3 (TSv3) results.
View Article and Find Full Text PDFDeubiquitinating enzyme USP2 alleviates muscle atrophy by stabilizing PPARγ.
Diabetes
January 2025
Department of Geriatrics, Peking University Shenzhen Hospital, Shenzhen, China.
Insulin resistance, a hallmark of type 2 diabetes, accelerates muscle breakdown and impairs energy metabolism. However, the role of Ubiquitin Specific Peptidase 2 (USP2), a key regulator of insulin resistance, in sarcopenia remains unclear. Peroxisome proliferator activated receptor γ (PPARγ) plays a critical role in regulating muscle atrophy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!